Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven years in an executive leadership role at Johnson & Johnson (J&J). While at J&J, he served as President of Centocor, Inc., a multi-billion-dollar subsidiary focused on the development and commercialization of industry-leading biomedicines used to treat chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for commercial product launches and continued the company’s legacy of double-digit growth for its flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler served as President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. He also had a successful 13-year career at Eli Lilly and Company where he held a variety of sales, marketing and business development roles with increasing responsibilities in the pharmaceutical and medical device divisions. Mr. Fowler received a B.S. in Pharmacy and an MBA from the University of North Carolina at Chapel Hill (UNC-CH).
Chief Financial Officer
Mr. Albury oversees all accounting, finance and business development matters for Liquidia. Before joining Liquidia in 2013, Mr. Albury served as the Chief Financial Officer of Osmotica Pharmaceutical Corp., a multinational specialty pharmaceutical company and a global leader in osmotic drug delivery with several products commercialized. Prior to that, he served as the CFO for KBI Biopharma, a global leader in contract biopharmaceutical drug development. Earlier in his career, Mr. Albury served as the CFO of Ardent Pharmaceuticals, a specialty pharmaceutical company with a broad drug portfolio based upon delta receptor pharmacology. He also spent 12 years in the Assurance & Business Advisory practice of Arthur Andersen, focused on the life sciences and healthcare industries. Mr. Albury is a Certified Public Accountant in North Carolina and Florida and earned his M.A. in Professional Accountancy at the University of Miami.
Chief Operations Officer
Mr. Lippe is responsible for all aspects of operations at Liquidia, including manufacturing, supply chain management, quality, facilities, and program management. Prior to joining Liquidia in 2015, Mr. Lippe served as an Executive Vice President of Operations and Chief Operations Officer at Alexza Pharmaceuticals. In these roles, he had operational oversight for the scale-up and optimization of supply that supported the launch of the company’s first commercial product, and he advanced a platform proof-of-concept which accelerated the company’s product pipeline. He also worked as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc., and as the Head of Manufacturing for Genentech’s Vacaville operations. Mr. Lippe spent 10 years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. He received his MPH and MBA degrees from the University of California, Berkeley, and received a B.S. degree in Marine Engineering from the United States Coast Guard Academy.
Senior Vice President, Research & Development
Dr. Maynor, a co-inventor of Liquidia’s PRINT® technology, directs and manages research and development at Liquidia. He has initiated several new drug delivery technology initiatives at Liquidia since joining the company in 2005, including programs in ophthalmology, inhaled drug delivery, and other therapeutic areas. Dr. Maynor earned a Ph.D. in Chemistry from Duke University, where he focused on nanotechnology and materials chemistry. He also holds a B.A. in Chemistry from Harvard University. He has co-authored over 20 peer-reviewed publications in the fields of drug delivery, nano-technology, and colloid science and is a co-inventor of several patents and patent applications in nano-technology and drug delivery
Senior Vice President, Product Development
Dr. Robert Roscigno is Senior Vice President, Product Development and program lead for LIQ861. Before joining Liquidia in September 2015, Dr. Roscigno served as Executive Vice President, Global Clinical Affairs at GeNO LLC, where he led the clinical development team working on a novel nitric oxide delivery system. Prior to joining GeNO in 2009, Dr. Roscigno served as President and COO of Lung Rx, Inc., where he was responsible for bringing the company’s lead product, Tyvaso®, successfully through Phase 3 development. Over a 10-year period, he served in multiple leadership positions at United Therapeutics Corporation where he helped transform the company from a start-up to a multi-billion-dollar company and was also a key contributor in the successful development and worldwide commercialization of Remodulin™ for the treatment of pulmonary arterial hypertension. Dr. Roscigno has more than 20 years of drug development experience relating to pulmonary hypertension, is the co-inventor on five U.S. patents and has published numerous articles in scientific journals. He received a Ph.D. in Cell and Molecular Biology from Duke University.
Senior Vice President, Clinical Development
Dr. Royal has been a senior pharmaceutical executive at several companies over the last 15 years holding various positions in Clinical Development and Medical Affairs. He has been responsible for several 505(b)(2) pain-related NDAs/MAAs, including Ofirmev® (IV acetaminophen) and Zalviso® (sublingual sufentanil), as well as NDAs/ANDAs in numerous other therapeutic areas. Dr. Royal also worked on the NDA/MAA for Prialt® (intraspinal ziconotide) and the early development of Embeda® (sustained release morphine with sequestered naltrexone). Dr. Royal is board certified in internal medicine, pain medicine, anesthesiology (with additional certification in pain management), addiction medicine and legal medicine. He has authored over 170 publications. Dr. Royal received his medical degree from the University of Massachusetts Medical School, a law degree from the University of Maryland School of Law, and a Global Executive MBA from TRIUM (NYU-Stern, HEC-Paris, and the London School of Economics).
Vice President, Business Development and Strategy
As Vice President, Business Development and Strategy at Liquidia, Mr. Adair is responsible for pursuing partnership and licensing opportunities for the company. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. He also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.
Head of Human Resources
As Head of Human Resources, Ms. Gordon-Krawchick is focused on building a team-based culture of innovation and excellence at Liquidia. In addition to leading the company’s workforce strategies and operations, she oversees recruiting and onboarding, training and leadership development, compensation planning and total rewards, organizational development, and corporate communications. Prior to joining Liquidia in 2010, Ms. Gordon-Krawchick held multiple Human Resources Business Partner roles at Johnson & Johnson (J&J) across research & development, sales, marketing, commercial and operations. She also led early talent recruitment and development for J&J’s commercial groups across the pharmaceutical businesses. Ms. Gordon-Krawchick received a business degree from George Washington University.
Our values stem from our core principals. They reflect what we care about at Liquidia and how we recognize the tremendous efforts of our team members.